Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The mixture of modified allergen extracts of 6 grasses + modified allergen extract of olive pollen is a subcutaneous allergen immunotherapy (SCIT) product developed by Inmunotek S.L. It is a polymerized allergoid formulation created by glutaraldehyde modification of extracts from six grass species (*Holcus lanatus*, *Dactylis glomerata*, *Lolium perenne*, *Phleum pratense*, *Poa pratensis*, and *Festuca elatior*) and olive tree (*Olea europaea*) pollen. This chemical modification reduces the IgE-binding capacity of the allergens, thereby minimizing the risk of systemic allergic reactions (anaphylaxis) during administration, while preserving their immunogenicity to induce protective IgG antibodies and T-cell tolerance. The drug is intended for patients co-sensitized to both grass and olive pollens who suffer from moderate-to-severe allergic rhinitis, rhinoconjunctivitis, and/or controlled mild-to-moderate asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixture of modified allergen extracts of 6 grasses + modified allergen extract of olive pollen.